Starpharma’s anti-viral nasal spray relaunched in UK

Starpharma (ASX:SPL) has announced that VIRALEZE nasal spray has been relaunched by LloydsPharmacy in the UK.

VIRALEZE is a nasal spray that physically traps and blocks cold and respiratory viruses in the nasal cavity.

Starpharma said the product has already been delivered to LloydsPharmacy’s distribution centre.

LloydsPharmacy is one of the largest pharmacy groups in the UK, and its affiliated wholesale arm, AAH, is also one of the largest pharmaceutical wholesalers in the UK, supplying over 14,000 independent UK pharmacies.

In the UK, Starpharma will supply VIRALEZE™ exclusively to LloydsPharmacy/AAH under its existing sales and distribution agreement.

Starpharma CEO Dr Jackie Fairley said, “We are delighted to relaunch Starpharma’s innovative nasal spray, VIRALEZE, in the UK through LloydsPharmacy’s extensive online and retail network. VIRALEZE will be particularly useful in the winter cold and flu season given its broad spectrum of activity against multiple cold and respiratory viruses.

“VIRALEZE is supported by multiple publications in peer-reviewed, international journals and was presented at leading, international antiviral conference, CROI, earlier this year.”

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.